PMID- 36482037
OWN - NLM
STAT- MEDLINE
DCOM- 20230113
LR  - 20230113
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
VI  - 43
IP  - 1
DP  - 2023 Jan
TI  - Long-Term Safety and Effectiveness of Erenumab in Patients with Migraine: A 
      Systematic Review and Single-Arm Meta-analysis.
PG  - 45-59
LID - 10.1007/s40261-022-01230-x [doi]
AB  - BACKGROUND AND OBJECTIVE: Several studies on use of erenumab for migraine 
      treatment have been published over recent years. However, its long-term safety 
      and effectiveness have not been consistently established in the literature yet. 
      We aimed to perform a qualitative and quantitative analysis of the long-term 
      safety and effectiveness of erenumab for the treatment of migraine headaches. 
      METHODS: Long-term follow-up was defined as >/= 1 year. PubMed, Embase and Cochrane 
      Library were systematically searched from inception to 14 June 2022 for studies 
      meeting the inclusion criteria. Risk of bias was assessed using the 
      Newcastle-Ottawa Scale. RESULTS: Fourteen studies, comprising 3574 patients, were 
      included. The total follow-up period ranged from 48 to 268 weeks (i.e., 1 year to 
      5.6 years). Pooled estimate rates for all adverse events (AEs) were 63% (95% CI 
      46-78); for serious AEs, 3% (95% CI 1-7); and for AEs leading to discontinuation 
      of erenumab, 3% (95% CI 2-5). Reduction in monthly migraine days (MMDs) was -6.98 
      (95% CI -8.90 to -5.05) and in migraine-specific medication days (MSMDs) was 
      - 6.09 (95% CI - 9.43 to - 2.75). More than half (57%; 95% CI 51-63) and around 
      one-third (35%; 95% CI 28-42) of patients presented with reductions of >/= 50% and 
      >/= 75% in MMDs, respectively. Headache Impact Test-6 (HIT-6) score was decreased 
      by -9.68 points (95% CI - 12.03 to - 7.34). Nine studies were considered of poor 
      methodological quality and five of fair quality. CONCLUSIONS: Erenumab has a 
      favorable safety profile, with a low incidence of serious AEs, and sustained 
      efficacy over >/=1 year of follow-up in the treatment of migraine.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Bomtempo, Fernanda Ferreira
AU  - Bomtempo FF
AUID- ORCID: 0000-0001-7268-6695
AD  - School of Medicine, Faculdade Ciencias Medicas de Minas Gerais (CMMG), Alameda 
      Ezequiel Dias, 275, Centro, Belo Horizonte, MG, 30130-110, Brazil. 
      febomtempo16@gmail.com.
FAU - Rocha, Rebeka Bustamante
AU  - Rocha RB
AD  - School of Medicine, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.
FAU - Cenci, Giulia Isadora
AU  - Cenci GI
AD  - School of Medicine, Faculdade Meridional (IMED), Passo Fundo, RS, Brazil.
FAU - Nager, Gabriela Borges
AU  - Nager GB
AD  - School of Medicine, Universidade Federal do Estado do Rio de Janeiro (UNIRIO), 
      Rio de Janeiro, RJ, Brazil.
FAU - Telles, Joao Paulo Mota
AU  - Telles JPM
AD  - Department of Neurology, Hospital das Clinicas da Faculdade de Medicina da 
      Universidade de Sao Paulo (HC-FMUSP), Sao Paulo, SP, Brazil.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20221208
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - I5I8VB78VT (erenumab)
RN  - 0 (Calcitonin Gene-Related Peptide Receptor Antagonists)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - *Calcitonin Gene-Related Peptide Receptor Antagonists/adverse effects
MH  - *Migraine Disorders/drug therapy
MH  - Antibodies, Monoclonal, Humanized/adverse effects
EDAT- 2022/12/10 06:00
MHDA- 2023/01/14 06:00
CRDT- 2022/12/09 00:30
PHST- 2022/11/16 00:00 [accepted]
PHST- 2022/12/10 06:00 [pubmed]
PHST- 2023/01/14 06:00 [medline]
PHST- 2022/12/09 00:30 [entrez]
AID - 10.1007/s40261-022-01230-x [pii]
AID - 10.1007/s40261-022-01230-x [doi]
PST - ppublish
SO  - Clin Drug Investig. 2023 Jan;43(1):45-59. doi: 10.1007/s40261-022-01230-x. Epub 
      2022 Dec 8.